EP 4084801 A1 20221109 - A NOVEL VISCOELASTIC FORMULATION FOR OSTEOARTHRITIS TREATMENT AND A PRODUCTION METHOD THEREOF
Title (en)
A NOVEL VISCOELASTIC FORMULATION FOR OSTEOARTHRITIS TREATMENT AND A PRODUCTION METHOD THEREOF
Title (de)
NEUARTIGE VISKOELASTISCHE FORMULIERUNG ZUR BEHANDLUNG VON OSTEOARTHRITIS UND VERFAHREN ZU IHRER HERSTELLUNG
Title (fr)
NOUVELLE FORMULATION VISCOÉLASTIQUE POUR LE TRAITEMENT DE L'ARTHROSE ET SON PROCÉDÉ DE PRODUCTION
Publication
Application
Priority
- TR 201922907 A 20191231
- TR 2020051471 W 20201231
Abstract (en)
[origin: WO2021137837A1] The present invention relates a novel viscoelastic formulation developed for osteoarthritis treatment, and a production method thereof. The objective of the present invention is to provide a viscoelastic gel comprising crosslinked hyaluronic acid, chondroitin sulfate and non-crosslinked hyaluronic acid (Linear HA) for use in intra- articular applications to relieve pain caused by Osteoarthritis (OA), to provide support for synovial fluid whose effectiveness has decreased, and to treat osteochondral lesions.
IPC 8 full level
A61K 31/728 (2006.01); A61K 31/737 (2006.01); A61P 19/02 (2006.01)
CPC (source: EP)
A61K 31/728 (2013.01); A61K 31/737 (2013.01); A61P 19/02 (2018.01); C08B 37/0072 (2013.01); C08J 3/075 (2013.01); C08L 5/08 (2013.01); C08J 2305/08 (2013.01)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021137837 A1 20210708; EP 4084801 A1 20221109; EP 4084801 A4 20240417; TR 201922907 A2 20210726; TR 201922945 A2 20210726
DOCDB simple family (application)
TR 2020051471 W 20201231; EP 20910352 A 20201231; TR 201922907 A 20191231; TR 201922945 A 20191231